Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab for allosensitization in heart transplant candidates
NCT04088903Phase 1Withdrawn
- Start
- Apr 2021
- Primary completion
- Apr 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of daratumumab in Allosensitization. Primary endpoint: Change in the number of individual preformed HLA antibodies at 12 weeks. Planned start Apr 2021; status: withdrawn.
02
Drugs
daratumumab
03
Conditions
Allosensitization
Beyond the preview
Go deeper on NCT04088903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04088903.